

# MBS Antibiogram 2024

GRAM NEGATIVE		ANTIBIOTICS														
1/1/2024-12/31/2024	Number tested	Amoxicillin/Clavulanic Acid	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin <sup>(a)</sup>	Levofloxacin	Meropenem	Nitrofurantoin	Piperacillin/Tazobactam	Tetracycline	Tobramycin	Trimeth/Sulfa
ORGANISM	PERCENT SUSCEPTIBLE															
<i>Escherichia coli</i>	664	88		89	96	94	74	#	79	75	100	95	97			78
<i>Klebsiella pneumoniae</i>	103	95		93	95	95	89	#	99	89	100	18	95			91
<i>Proteus mirabilis</i>	82	84		84	91	88	70	#	88	70	100	0	100			66
<i>Pseudomonas aeruginosa</i>	82				88		72			71	91		87			

GRAM POSITIVE		ANTIBIOTICS										
1/1/2024-12/31/2024	Number tested	Ampicillin	Clindamycin	Erythromycin	Gentamicin (High-Level)	Linezolid	Nitrofurantoin	Oxacillin	Streptomycin (High-Level)	Tetracycline	Trimeth/Sulfa	Vancomycin
Organism	PERCENT SUSCEPTIBLE											
<i>Enterococcus faecalis</i>	91	99		8	78	100	99		94	22		99
<i>Staphylococcus aureus, ALL</i>	230		68	34		100		49		82	77	100
<i>MRSA only</i>	112		57	8		100		0		76	59	100
<i>MSSA only</i>	118		79	61		100		100		88	95	100
<i>Staphylococcus epidermidis</i>	47		50	26		100		28		74	53	100

85-100% Susceptible

60-84% Susceptible

<60% Susceptible

# Not routinely tested. Historical data suggests frequent susceptibility; confirm with microbiology when relevant

• Due to the presence of inducible beta-lactamases, this organism should be considered resistant to the antimicrobial indicated

Shaded boxes indicate organism/antimicrobial combinates not tested routinely

(a) Aminoglycoside breakpoints were lowered in 2023 for Enterobacterales and *Pseudomonas aeruginosa*. Gentamicin should no longer be used for the treatment of *Pseudomonas aeruginosa* infections.